Propanc Biopharma Inc PPCB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.59
- Day Range
- $1.40–1.50
- 52-Week Range
- $1.31–234.00
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 2.28M
- Market Cap
- $3.39M
- Volume/Avg
- 151,194 / 4M
Key Statistics
- Price/Earnings (Normalized)
- 0.00
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 2
- Website
- https://www.propanc.com
Valuation
|
Metric
|
PPCB
|
|---|---|
Price/Earnings (Normalized) | 0.00 |
Price/Book Value | 0.13 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
PPCB
Financial Strength
|
Metric
|
PPCB
|
|---|---|
Quick Ratio | 0.13 |
Current Ratio | 2.37 |
Interest Coverage | −26.93 |
Quick Ratio
PPCB
Profitability
|
Metric
|
PPCB
|
|---|---|
Return on Assets (Normalized) | −62.40% |
Return on Equity (Normalized) | −83.88% |
Return on Invested Capital (Normalized) | −71.55% |
Return on Assets
PPCB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|K?yF&<Y | LOCK|^T?y | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|NwpJSl | LOCK|kJtD | $71B | |||
| argenx SE ADR
ARGX
| LOCK|$Q^c?sS | LOCK|s$ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|^HS&r$S | LOCK|<XX | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|>Z@>BJ | LOCK|jxm%Y | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<$^X#K?# | LOCK|W^$qz | $26B | |||
| Moderna Inc
MRNA
| LOCK|@%z!b& | LOCK|xTj | $25B | |||
| Incyte Corp
INCY
| LOCK|pFrZZZ> | LOCK|L% | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|l@zM&# | LOCK|M$w | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|x@$ZG>! | LOCK|!$Z | $16B |
United States